

Vitamin D and Cognition: Are There Any Cautions Against Intervention Trials for Older Adults?

Celeste A. de Jager*

Division of Geriatric Medicine, Department of Medicine, University of Cape Town, South Africa

*Corresponding author: CA de Jager, Institute of Ageing, L51, OMB, Groote Schuur Hospital, Observatory 7925, Cape Town, Western Cape, South Africa, Tel: +27-0-21 4066538; E-mail: Celeste.DeJager@uct.ac.za

Rec date: May 28, 2014, Acc date: May 29, 2014, Pub date: May 31, 2014

Copyright: © 2014 CA de Jager. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Vitamin D has long been known as the sunshine vitamin, as it is synthesized in the skin from 7-dehydrocholesterol in the presence of sunlight. It is known for its role in strengthening bones through metabolic processing of calcium. The main circulating metabolite form of vitamin D is 25-hydroxyvitamin D (25(OH)D); this is processed mainly via the liver and kidneys to the active form, 1,25(OH)₂D, which is water soluble. Extra-renal cells can also produce 1,25(OH)₂D. Blood levels are controlled by the parathyroid hormone, growth factors, cytokines and calcium [1]. Deficiencies of vitamin D are linked to conditions such as rickets in children and osteoporosis, falls and fractures in older adults, as well as some psychiatric conditions such as depression and seasonal affective disorder (SAD) [2].

Surveys suggest that up to a third of the populations in the Western World may be D vitamin deficient, depending on the lower limit for normal serum levels [3]. Levels vary seasonally, although exposure to sunshine is not absolutely necessary, if dietary sources and supplements are sufficient. Sources of vitamin D include oily fish, eggs, fish oils such as cod liver oil and liver. Vegan sources include lichen for vitamin D₃, cholecalciferol, and mushrooms and alfalfa for D₂, ergocalciferol. Vitamin D₃ supplementation has been shown to be more efficacious than D₂ in increasing levels of serum 25(OH)D, possibly due to more rapid clearance of vitamin D(2), or other mechanisms [4]. Fortification of milk, milk products, and flour may also supplement intake in certain countries. Older adults are more prone to deficiency due to thinning of the skin and decreasing amounts of dehydrocholesterol, accompanied by less absorption of sunlight and conversion to the active form. Low dietary intake and poorer absorption by the gut, limited sunlight exposure and limited physical activity may also contribute to deficiency.

Health claims for vitamin D supplements include maintenance of a normal immune system and inflammatory responses, reduction in falls, fractures and osteoporosis. However, recent research has shown links between vitamin D deficiency (25(OH)D) and increases in the incidence of hypertension, hyperlipidaemia, diabetes, myocardial infarction and stroke [3]. These conditions are associated with increased risk of neurodegenerative diseases such as vascular dementia, Alzheimer's disease (AD) and Parkinson's disease. Cross-sectional and longitudinal observational studies used for a meta-analysis [5] showed associations of low 25(OH)D with cognitive impairment and decline in older adults. Generally, deficiency or low 25(OH)D was equated to serum levels below 20ng/ml, while normal levels ranged between 20–50 ng/ml. Meta-analyses have confirmed significantly lower levels of vitamin D in Alzheimer's disease patients and in those with mild cognitive impairment (MCI) compared to normal controls [6].

A meta-analysis reviewed by van der Schaft et al. [7] suggested a more than doubled risk of cognitive impairment in patients with vitamin D deficiency among 7,688 participants. 67% (4/6) of the prospective studies showed a higher risk of cognitive decline after a follow-up period of 4–7 years in participants with lower 25(OH)D levels at baseline compared with participants with higher 25(OH)D levels. Depending on the cognitive status of those included in these studies, reverse causation limits the interpretability of the findings, as cognitive impairment may be the cause of poor nutritional status.

Reduced risk of AD has been associated with higher vitamin D levels [5]. Additionally, reduced risk of cognitive impairment, higher concentrations of CSF Aβ_{1–42} and greater brain volumes (e.g. white matter and structures belonging to medial temporal lobe) were found in patients attending a memory clinic who had higher serum 25(OH)D [8].

A biological rationale for the effect of vitamin D on cognitive performance is plausible. Vitamin D receptors have been located in many brain regions (including the hippocampus) [9] associated with cognitive functions that decline with the development of dementia. Vitamin D correlates negatively with cerebral ventricle size, suggesting that it contributes to brain atrophy [10]. It has been suggested that the anti-ischaemic, anti-inflammatory and anti-oxidant roles of vitamin D are neuroprotective and vasoprotective [8,11]. In addition, various functions of vitamin D in neurotransmitter metabolism, particularly in the dopaminergic system, have been proposed [9]. Overexpression of the vitamin D receptor in the brain, or vitamin D treatment, may suppress amyloid precursor protein transcription [12].

Most intervention trials with vitamin D supplements have shown improvements in bone health and reduction in falls [4]. However, clinical trials for cognitive benefit are few. One showed no benefit for cognitive performance after 4 weeks of supplementation [13]. Another showed a benefit for executive function in older adults who were prescribed vitamin D for any reason compared to patients who were not [14]. A small 6-month controlled trial reported that a combination of memantine+vitamin D was superior to memantine alone and vitamin D alone in preventing cognitive decline among AD participants [15].

There is little evidence from existing trials that vitamin D above current reference intakes is harmful. In most trials, reports of hypercalcaemia and hypercalciuria were not associated with clinically relevant events [4]. The Women's Health Initiative study did report a small increase in kidney stones in postmenopausal women on high levels of calcium supplements (1000mg) and normal D₃ intake. The increase in renal stones corresponded to 5.7 events per 10,000 person-years of exposure.

Side effects of high vitamin D levels are mostly associated with effects of increased calcium and include vascular calcification and kidney stones. Vitamin D overdose causes hypercalcaemia, and may contribute to renal failure in extreme cases [16].

Thus, the evidence is not convincing enough to recommend regular high dosing with vitamin D for older adults. However, more clinical trials are needed as there appears to be sufficient epidemiological evidence to recommend treatment of vitamin D deficiency to benefit cognitive function, perhaps in a window of time for older adults with or without cognitive impairment. Vitamin D supplements combined with other memory enhancers may be more effective than vitamins alone for those with dementia.

References

1. Holick MF (2007) Vitamin D deficiency. *N Engl J Med* 357: 266-281.
2. Anglin RE, Samaan Z, Walter SD, McDonald SD (2013) Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br J Psychiatry* 202: 100-107.
3. Schlögl M, Holick MF (2014) Vitamin D and neurocognitive function. *Clin Interv Aging* 9: 559-568.
4. Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, et al. (2007) Effectiveness and safety of vitamin D in relation to bone health. *Evid Rep Technol Assess (Full Rep)* : 1-235.
5. Balion C, Griffith LE, Striffler L, Henderson M, Patterson C, et al. (2012) Vitamin D, cognition, and dementia: a systematic review and meta-analysis. *Neurology* 79: 1397-1405.
6. Annweiler C, Llewellyn DJ, Beauchet O (2013) Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis* 33: 659-674.
7. van der Schaft J, Koek HL, Dijkstra E, Verhaar HJ, van der Schouw YT, et al. (2013) The association between vitamin D and cognition: A systematic review. *Ageing Res Rev* 12: 1013-1023.
8. Hooshmand B, Löök J, Solomon A, Mangialasche F, Miralbell J, et al. (2014) Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. *J Gerontol A Biol Sci Med Sci*.
9. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J Chem Neuroanat* 29: 21-30.
10. Annweiler C, Montero-Odasso M, Hachinski V, Seshadri S, Bartha R, et al. (2013) Vitamin D concentration and lateral cerebral ventricle volume in older adults. *Mol Nutr Food Res* 57: 267-276.
11. Briones TL, Darwish H (2012) Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. *J Neuroinflammation* 9: 244.
12. Wang L, Song Y, Manson JE, Pilz S, März W, et al. (2012) Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. *Circ Cardiovasc Qual Outcomes* 5: 819-829.
13. Przybelski R, Agrawal S, Krueger D, Engelke JA, Walbrun F, et al. (2008) Rapid correction of low vitamin D status in nursing home residents. *Osteoporos Int* 19: 1621-1628.
14. Annweiler C, Fantino B, Gautier J, Beaudenon M, Thiery S, et al. (2012) Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre-post study. *J Am Geriatr Soc* 60: 793-795.
15. Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O (2012) Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. *Cogn Behav Neurol* 25: 121-127.
16. Vitamin D in Merck Manual of Diagnosis and Therapy, Professional Edition.